Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

NCT03876028 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: Tisagenlecleucel
DRUG: Ibrutinib

Sponsor

Novartis Pharmaceuticals